Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fumarylacetoacetate hydrolase domain-containing protein 1 (FAHD1) is a 24-kDa mitochondrial enzyme encoded by the FAHD1 gene. It belongs to the fumarylacetoacetate hydrolase superfamily and displays bifunctional enzymatic activities: oxaloacetate decarboxylase (ODx), which catalyzes the conversion of oxaloacetate (OAA) to pyruvate and CO₂, and acylpyruvate hydrolase (ApH), which hydrolyzes acetylpyruvate and fumarylpyruvate[1][3][6][9]. FAHD1 is a key regulator of mitochondrial metabolism, modulating cellular energy production by regulating OAA levels, TCA cycle flux, and ROS production, thereby impacting cell proliferation, senescence, and survival[2][5][7]. FAHD1's expression is tissue-dependent (kidney, liver) and is implicated in various pathophysiological states, including cancer and reproductive disorders[5][7]. Its structure consists of a conserved catalytic center shared within the superfamily, with species-specific sequence variability enabling selective antibody recognition and post-translational regulatory modifications[1][9]. If more structural, ligand, or inhibitor information becomes available, FAHD1 may emerge as a direct pharmacological target for diseases related to mitochondrial dysfunction or metabolic imbalance.
For in-development therapeutics, likely inhibition or modulation of FAHD1’s oxaloacetate decarboxylase activity, affecting mitochondrial OAA levels, TCA cycle flux, and ROS production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fumarylacetoacetate hydrolase domain-containing protein 1 (FAHD1).